Whats new

Whats new.

Baird - Efti Shows Favorable Trend on ORR in Phase 2b Trial in HNSCC; Maintain OP, $6 PT (Analyst: Joel L. Beatty, MD)

June 27th 2024

For a copy of this research report please contact your Baird advisor

Go back